Current Understanding of Mycobacterium tuberculosis Drug Resistances and Diagnostics in Indonesia: A Review

Ayu Rahayu; Anwar Rovik; Oktaviani Naulita Turnip

doi:10.52365/jecp.v4i2.1121

Current Understanding of Mycobacterium tuberculosis Drug Resistances and Diagnostics in Indonesia: A Review

Ayu Rahayu, Anwar Rovik, Oktaviani Naulita Turnip

Abstract

Tuberculosis is a significant global infectious disease cause of mortality, with 25% of the world's population caused by Mycobacterium tuberculosis (Mtb). The highest case recorded was 821,200 cases in 2023 over one decade. Drug resistance significantly impacts tuberculosis treatment and has been observed since the first drug discovery, streptomycin. In Indonesia, drug-resistant tuberculosis (DR-TB) is a significant public health issue, with an estimated 24,666 cases recorded in 2022. A comparative literature search was conducted using various articles, including research studies, guidelines, narrative reviews, reports, and meta-analyses, with the inclusion criteria for reference sources including ten years of published articles. Drug resistance in TB can reduce treatment success rate and increase therapy duration. In the result, several general mechanisms proposed for drug resistance in Mtb include efflux pump, enzyme inactivation, permeability barrier, mutations in drug-target genes, and epigenetics. Currently, TB treatment in Indonesia involves combination therapy using three or more types of drugs, such as rifampicin and isoniazid. The International Standard for TB Care (ISTC) serves as the basis for TB diagnosis in Indonesia, which involves a combination of clinical and laboratory tests. Early diagnosis and universal access to the Drug Susceptibility Test (DST) are crucial for TB resistance. In Indonesia, several diagnostic methods, such as sequencing, PCR testing, Gene Xpert, and culture, can be used to identify TB resistance. Understanding the mechanisms of drug resistance and developing effective diagnosis strategies for TB resistance is crucial for managing global infection.

Keywords

Mycobacterium tuberculosis; drug-resistant; diagnostic; Indonesia

Full Text:

PDF

References

Abraham, Ayanwale O. 2020. “Mechanism of Drug Resistance in Mycobacterium tuberculosis.” American Journal of Biomedical Science & Research 7 (5): 378–83. https://doi.org/10.34297/AJBSR.2020.07.001181.

Adilistya, Tika. 2016. “Manfaat Pemeriksaan Interferon-Gamma Release Assay untuk Diagnosis Tuberkulosis di Indonesia” 43 (7): 545–50. https://doi.org/10.55175/cdk.v43i7.86.

Andries, Koen, Cristina Villellas, Nele Coeck, Kim Thys, Tom Gevers, Luc Vranckx, Nacer Lounis, Bouke C. de Jong, and Anil Koul. 2014. “Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline.” PloS One 9 (7): e102135. https://doi.org/10.1371/journal.pone.0102135.

Chaidir, L., S. Sengstake, J. De Beer, H. Krismawati, F. D. Lestari, S. Ayawaila, D. Van Soolingen, R. Anthony, R. Van Crevel, and B. Alisjahbana. 2015. “Mycobacterium tuberculosis Genotypic Drug Resistance Patterns and Clustering in Jayapura, Papua, Indonesia.” The International Journal of Tuberculosis and Lung Disease 19 (4): 428–33. https://doi.org/10.5588/ijtld.14.0350.

Chaidir, Lidya, Carolien Ruesen, Bas E. Dutilh, Ahmad R. Ganiem, Anggriani Andryani, Lika Apriani, Martijn A. Huynen, et al. 2019. “Use of Whole-Genome Sequencing to Predict Mycobacterium tuberculosis Drug Resistance in Indonesia.” Journal of Global Antimicrobial Resistance 16 (March):170–77. https://doi.org/10.1016/j.jgar.2018.08.018.

Christopher, PaulusMario, Cucunawangsih, and Allen Widysanto. 2019. “GeneXpert Mycobacterium tuberculosis/Rifampicin Assay for Molecular Epidemiology of Rifampicin-Resistant Mycobacterium tuberculosis in an Urban Setting of Banten Province, Indonesia.” International Journal of Mycobacteriology 8 (4): 351. https://doi.org/10.4103/ijmy.ijmy_138_19.

Cohen, Keira A., William R. Bishai, and Alexander S. Pym. 2014. “Molecular Basis of Drug Resistance in Mycobacterium Tuberculosis.” Edited by Graham F. Hatfull and William R. Jacobs Jr. Microbiology Spectrum 2 (3): 2.3.07. https://doi.org/10.1128/microbiolspec.MGM2-0036-2013.

Colangeli, Roberto, Aditi Gupta, Solange Alves Vinhas, Uma Deepthi Chippada Venkata, Soyeon Kim, Courtney Grady, Edward C. Jones-López, et al. 2020. “Mycobacterium tuberculosis Progresses through Two Phases of Latent Infection in Humans.” Nature Communications 11 (1): 4870. https://doi.org/10.1038/s41467-020-18699-9.

Danilchanka, Olga, David Pires, Elsa Anes, and Michael Niederweis. 2015. “The Mycobacterium tuberculosis Outer Membrane Channel Protein CpnT Confers Susceptibility to Toxic Molecules.” Antimicrobial Agents and Chemotherapy 59 (4): 2328–36. https://doi.org/10.1128/AAC.04222-14.

Dewi, Atit Puspitasari. 2020. “Prevalence and Characteristic of Drug-Resistant Tuberculosis Patients in South Halmahera District, Eastern Indonesia.” In Tuberculosis, 505. European Respiratory Society. https://doi.org/10.1183/13993003.congress-2020.505.

Dookie, Navisha, Azraa Khan, Nesri Padayatchi, and Kogieleum Naidoo. 2022. “Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field.” Frontiers in Microbiology 13 (March):775030. https://doi.org/10.3389/fmicb.2022.775030.

Falzon, Dennis, Neel Gandhi, Giovanni B. Migliori, Giovanni Sotgiu, Helen S. Cox, Timothy H. Holtz, Maria-Graciela Hollm-Delgado, et al. 2013. “Resistance to Fluoroquinolones and Second-Line Injectable Drugs: Impact on Multidrug-Resistant TB Outcomes.” European Respiratory Journal 42 (1): 156–68. https://doi.org/10.1183/09031936.00134712.

Farlina, Lita, Finny Fitry Yani, Darfioes Basir, and Hafni Bachtiar. 2016. “Perbandingan Uji Tuberkulin dengan Kadar Interferon Gamma pada Kultur Sel Limfosit Anak Tersangka TB.” Sari Pediatri 16 (4): 260. https://doi.org/10.14238/sp16.4.2014.260-5.

Farnia, Parissa, Saeid Besharati, Poopak Farina, Saman Ayoubi, Majid Marjani, Jalaledin Ghanavi, Payam Tabarsi, and Ali Akbar Velayati. 2024. “The Role of Efflux Pumps Transporter in Multi-Drug Resistant Tuberculosis: Mycobacterial Memberane Protein (MMPL5).” The International Journal of Mycobacteriology 13 (1): 7–14. https://doi.org/10.4103/ijmy.ijmy_37_24.

Fenner, Lukas, Matthias Egger, Thomas Bodmer, Ekkehardt Altpeter, Marcel Zwahlen, Katia Jaton, Gaby E. Pfyffer, et al. 2012. “Effect of Mutation and Genetic Background on Drug Resistance in Mycobacterium tuberculosis.” Antimicrobial Agents and Chemotherapy 56 (6): 3047–53. https://doi.org/10.1128/AAC.06460-11.

Flores, Anthony R., Linda M. Parsons, and Martin S. Pavelka,. 2005. “Genetic Analysis of the β-Lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and Susceptibility to β-Lactam Antibiotics.” Microbiology 151 (2): 521–32. https://doi.org/10.1099/mic.0.27629-0.

Galagan, James E. 2014. “Genomic Insights into Tuberculosis.” Nature Reviews Genetics 15 (5): 307–20. https://doi.org/10.1038/nrg3664.

Gilpin, Christopher, A. Korobitsyn, and K. Weyer. 2016. “Current Tools Available for the Diagnosis of Drug-Resistant Tuberculosis.” Therapeutic Advances in Infectious Disease 3 (6): 145–51. https://doi.org/10.1177/2049936116673553.

Giraud-Gatineau, Alexandre, Juan Manuel Coya, Alexandra Maure, Anne Biton, Michael Thomson, Elliott M. Bernard, Jade Marrec, et al. 2020. “The Antibiotic Bedaquiline Activates Host Macrophage Innate Immune Resistance to Bacterial Infection.” eLife 9 (May):e55692. https://doi.org/10.7554/eLife.55692.

Goossens, Sander N., Samantha L. Sampson, and Annelies Van Rie. 2020. “Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis.” Clinical Microbiology Reviews 34 (1): e00141-20. https://doi.org/10.1128/CMR.00141-20.

Jena, Lingaraja, Pranita Waghmare, Supriya Kashikar, Satish Kumar, and Bhaskar C. Harinath. 2014. “Computational Approach to Understanding the Mechanism of Action of Isoniazid, an Anti-TB Drug.” International Journal of Mycobacteriology 3 (4): 276–82. https://doi.org/10.1016/j.ijmyco.2014.08.003.

Joshi, Hemant, Divya Kandari, and Rakesh Bhatnagar. 2021. “Insights into the Molecular Determinants Involved in Mycobacterium Tuberculosis Persistence and Their Therapeutic Implications.” Virulence 12 (1): 2721–49. https://doi.org/10.1080/21505594.2021.1990660.

Juliasih, Njoman. 2020. “Comparative Evaluation of Microscopy and Loop-Mediated Isothermal Amplification (LAMP) Assay for the Diagnosis of Tuberculosis.” Indian Journal of Forensic Medicine & Toxicology, July. https://doi.org/10.37506/ijfmt.v14i3.10749.

Karuniawati, Anis, Erlina Burhan, Eko Budi Koendhori, Desvita Sari, Budi Haryanto, Titik Nuryastuti, A. A. A. Yuli Gayatri, et al. 2023. “Performance of Xpert MTB/RIF and Sputum Microscopy Compared to Sputum Culture for Diagnosis of Tuberculosis in Seven Hospitals in Indonesia.” Frontiers in Medicine 9 (January):909198. https://doi.org/10.3389/fmed.2022.909198.

Khawbung, Jessy Lallungawi, Durbba Nath, and Supriyo Chakraborty. 2021. “Drug Resistant Tuberculosis: A Review.” Comparative Immunology, Microbiology and Infectious Diseases 74 (February):101574. https://doi.org/10.1016/j.cimid.2020.101574.

Koentjoro, M P, D S Rahayu, A Donastin, and E N Prasetyo. 2021. “Evaluation of Mycobacterium tuberculosis ripA Gene to Detect Antibiotic Resistance.” Journal of Physics: Conference Series 1918 (5): 052014. https://doi.org/10.1088/1742-6596/1918/5/052014.

Kumari, Pinki, Jiwesh Kumar Thakur, Prashant Kumar, Rakesh Kumar, and Deval Parekh. 2020. “Comparison of LJ Medium and BACTEC MGIT 960 Culture System for the Diagnosis of Tuberculosis.” Journal of Clinical and Diagnostic Research 14 (12): 9-13. https://doi.org/10.7860/JCDR/2020/46890.14304.

Kurniati, Anita, Desak Nyoman Surya Suameitra Dewi, and Ni Nyoman Purwani. 2019. “Rapid and Spesific Detection of Mycobacterium tuberculosis using Polymerase Chain Reaction.” Journal of Vocational Health Studies 3 (2): 83. https://doi.org/10.20473/jvhs.V3.I2.2019.83-88.

Li, Yang, Feng Sun, and Wenhong Zhang. 2019. “Bedaquiline and Delamanid in the Treatment of Multidrug-Resistant Tuberculosis: Promising but Challenging.” Drug Development Research 80 (1): 98–105. https://doi.org/10.1002/ddr.21498.

Machado, Diana, João Perdigão, Jorge Ramos, Isabel Couto, Isabel Portugal, Claudia Ritter, Erik C. Boettger, and Miguel Viveiros. 2013. “High-Level Resistance to Isoniazid and Ethionamide in Multidrug-Resistant Mycobacterium tuberculosis of the Lisboa Family is Associated with inhA Double Mutations.” Journal of Antimicrobial Chemotherapy 68 (8): 1728–32. https://doi.org/10.1093/jac/dkt090.

Maladan, Yustinus, Hana Krismawati, Tri Wahyuni, Ratna Tanjung, Kamla Awaludin, Kholis Abdurachim Audah, and Arli Aditya Parikesit. 2021. “The Whole-Genome Sequencing in Predicting Mycobacterium tuberculosis Drug Susceptibility and Resistance in Papua, Indonesia.” BMC Genomics 22 (1): 844. https://doi.org/10.1186/s12864-021-08139-3.

Martin, Anandi, Yasmine Bouyakoub, Kate Soumillion, Eléonore Ngyuvula Mantu, Alexandre Colmant, and Hector Rodriguez-Villalobos. 2020. “Targeting Bedaquiline Mycobacterial Efflux Pump to Potentially Enhance Therapy in Mycobacterium abscessus.” The International Journal of Mycobacteriology 9 (1): 71–75. https://doi.org/10.4103/ijmy.ijmy_181_19.

Martinelli, Daniel J., and Martin S. Pavelka. 2016. “The RipA and RipB Peptidoglycan Endopeptidases are Individually Nonessential to Mycobacterium smegmatis.” Journal of Bacteriology 198 (9): 1464–75. https://doi.org/10.1128/JB.00059-16.

Mertaniasih, NiMade, DesakNyoman Surya Suameitria Dewi, Soedarsono Soedarsono, Anita Kurniati, Ali Rohman, Zakiyathun Nuha, and Sohkichi Matsumoto. 2021. “The espD Full Gene as a Potential Biomarker in Active Pulmonary Tuberculosis.” International Journal of Mycobacteriology 10 (4): 421. https://doi.org/10.4103/ijmy.ijmy_198_21.

Ministry of Health RI. 2023. “Laporan Program Penanggulangan Tuberkulosis 2022.” Jakarta

Miotto, Paolo, Daniela M. Cirillo, and Giovanni Battista Migliori. 2015. “Drug Resistance in Mycobacterium tuberculosis.” Chest 147 (4): 1135–43. https://doi.org/10.1378/chest.14-1286.

Miotto, Paolo, Ying Zhang, Daniela Maria Cirillo, and Wing Cheong Yam. 2018. “Drug Resistance Mechanisms and Drug Susceptibility Testing for Tuberculosis.” Respirology 23 (12): 1098–1113. https://doi.org/10.1111/resp.13393.

Muttaqin, Z., Massi, M. N., Sjahril, R., Halik, H., Junaedi, M. A., Rifqiani, N., Safitri, N. I., et al. 2023. “Detection of rpoB Gene Mutations in Clinical Isolates of Rifampicin-Resistant Mycobacterium tuberculosis in Makassar City, South Sulawesi, Indonesia.” Malaysian Journal of Microbiology, August. https://doi.org/10.21161/mjm.220133.

Narang, Anshika, Astha Giri, Shraddha Gupta, Kushal Garima, Mridula Bose, and Mandira Varma-Basil. 2017. “Contribution of Putative Efflux Pump Genes to Isoniazid Resistance in Clinical Isolates of Mycobacterium tuberculosis.” International Journal of Mycobacteriology 6 (2): 177. https://doi.org/10.4103/ijmy.ijmy_26_17.

Niki, Mamiko, Maho Suzukawa, Shunsuke Akashi, Hideaki Nagai, Ken Ohta, Manabu Inoue, Makoto Niki, et al. 2015. “Evaluation of Humoral Immunity to Mycobacterium tuberculosis -Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development.” Journal of Immunology Research 2015: 1–13. https://doi.org/10.1155/2015/527395.

Novianti, Novianti, Oster Suriani Simarmata, and Dina Bisara Lolong. 2020. “Pemanfaatan Tes Cepat Molekuler (TCM) Genexpert sebagai Alat Diagnostik TB Paru di RSUD Wangaya Kota Denpasar.” Jurnal Ekologi Kesehatan 18 (3): 135–48. https://doi.org/10.22435/jek.v3i18.2399.

Noviyani, Alvera. 2020. “Variation of Tuberculosis Prevalence across Diagnostic Approaches and Geographical Areas of Indonesia.” Master of Science, Bangkok, Thailand: Chulalongkorn University. https://doi.org/10.58837/CHULA.THE.2020.252.

Oudghiri, Amal, Hind Karimi, Fouad Chetioui, Fathiah Zakham, Jamal Eddine Bourkadi, My Driss Elmessaoudi, Amin Laglaoui, Imane Chaoui, and Mohammed El Mzibri. 2018. “Molecular Characterization of Mutations Associated with Resistance to Second-Line Tuberculosis Drug among Multidrug-Resistant Tuberculosis Patients from High Prevalence Tuberculosis City in Morocco.” BMC Infectious Diseases 18 (1): 98. https://doi.org/10.1186/s12879-018-3009-9.

Papakonstantinou, Danai, Steven J. Dunn, Simon J. Draper, Adam F. Cunningham, Matthew K. O’Shea, and Alan McNally. 2021. “Mapping Gene-by-Gene Single-Nucleotide Variation in 8,535 Mycobacterium tuberculosis Genomes: a Resource to Support Potential Vaccine and Drug Development.” Edited by Jacqueline M. Achkar. mSphere 6 (2): e01224-20. https://doi.org/10.1128/mSphere.01224-20.

Purkan, P., I. Ihsanawati, D. Natalia, Y. M. Syah, D. S. Retnoningrum, and I. Siswanto. 2018. “Molecular Analysis of katG Encoding Catalase-Peroxidase from Clinical Isolate of Isoniazid-Resistant Mycobacterium tuberculosis.” Journal of Medicine and Life 11 (2): 160–67.

Putri, Linda Wahyuni, and Budi Hartono. 2024. “Literature Review: Cost Effectiveness Analysis Xpert MTB/RIF dibandingkan dengan Sputum Smear Microscopy untuk Diagnosis Tuberkulosis di Indonesia.” Indonesian of Health Information Management Journal (INOHIM) 11 (2): 105–13. https://doi.org/10.47007/inohim.v11i2.517.

Rawat, Richa, Adrian Whitty, and Peter J. Tonge. 2003. “The Isoniazid-NAD Adduct Is a Slow, Tight-Binding Inhibitor of InhA, the Mycobacterium tuberculosis Enoyl Reductase: Adduct Affinity and Drug Resistance.” Proceedings of the National Academy of Sciences of the United States of America 100 (24): 13881–86. https://doi.org/10.1073/pnas.2235848100.

Rukmana, Andriansjah, Cynthia Gozali, and Linda Erlina. 2024. “Mycobacterium Tuberculosis Lineage Distribution Using Whole-Genome Sequencing and Bedaquiline, Clofazimine, and Linezolid Phenotypic Profiles among Rifampicin-Resistant Isolates from West Java, Indonesia.” Edited by Todd R. Callaway. International Journal of Microbiology 2024 (March):1–9. https://doi.org/10.1155/2024/2037961.

Safithri, Fathiyah. 2011. “Diagnosis TB Dewasa dan Anak Berdasarkan ISTC 57.” Ejournal UMM 7 (15): 57-67.

Seifert, Marva, Donald Catanzaro, Antonino Catanzaro, and Timothy C. Rodwell. 2015. “Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review.” Edited by Igor Mokrousov. PLOS ONE 10 (3): e0119628. https://doi.org/10.1371/journal.pone.0119628.

Setyawan, MuhamadFrendy, NiMade Mertaniasih, S Soedarsono, Zakiyathun Nuha, Yustinus Maladan, and Sohkichi Matsumoto. 2023. “Mycobacterium tuberculosis–atpE Gene Profile of Bedaquiline-Treated Pulmonary Tuberculosis Patients at the Referral Hospital Dr. Soetomo, Indonesia.” International Journal of Mycobacteriology 12 (2): 122. https://doi.org/10.4103/ijmy.ijmy_40_23.

Seung, Kwonjune J., Salmaan Keshavjee, and Michael L. Rich. 2015. “Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis.” Cold Spring Harbor Perspectives in Medicine 5 (9): a017863. https://doi.org/10.1101/cshperspect.a017863.

Sharma, Sharda, Rahul Pal, Saif Hameed, and Zeeshan Fatima. 2016. “Antimycobacterial Mechanism of Vanillin Involves Disruption of Cell-Surface Integrity, Virulence Attributes, and Iron Homeostasis.” International Journal of Mycobacteriology 5 (4): 460–68. https://doi.org/10.1016/j.ijmyco.2016.06.010.

Singh, Aditi, Sonam Grover, Siddharth Sinha, Mriganko Das, Pallavi Somvanshi, and Abhinav Grover. 2017. “Mechanistic Principles Behind Molecular Mechanism of Rifampicin Resistance in Mutant RNA Polymerase Beta Subunit of Mycobacterium tuberculosis.” Journal of Cellular Biochemistry 118 (12): 4594–4606. https://doi.org/10.1002/jcb.26124.

Soeroto, Arto Yuwono, Bony Wiem Lestari, Prayudi Santoso, Lidya Chaidir, Basti Andriyoko, Bachti Alisjahbana, Reinout Van Crevel, and Philip C. Hill. 2019. “Evaluation of Xpert MTB-RIF Guided Diagnosis and Treatment of Rifampicin-Resistant Tuberculosis in Indonesia: A Retrospective Cohort Study.” Edited by Helen Cox. PLOS ONE 14 (2): e0213017. https://doi.org/10.1371/journal.pone.0213017.

Suryawan. S, Dwi Ari, and Tiodora Hadumaon Siagian. 2021. “Sex and Age Group Differences in The Spread of Tuberculosis in Indonesia: an Agent Based Modeling Approach.” Jurnal Aplikasi Statistika & Komputasi Statistik 13 (2): 47–60. https://doi.org/10.34123/jurnalasks.v13i2.342.

Susilawati, Tri Nugraha, and Riska Larasati. 2019. “A Recent Update of the Diagnostic Methods for Tuberculosis and Their Applicability in Indonesia: A Narrative Review.” Medical Journal of Indonesia 28 (3): 284–91. https://doi.org/10.13181/mji.v28i3.2589.

Tania, Tryna, Pratiwi Sudarmono, R. Lia Kusumawati, Andriansjah Rukmana, Wahyu Agung Pratama, Sanjib Mani Regmi, Orawee Kaewprasert, Angkana Chaiprasert, Virasakdi Chongsuvivatwong, and Kiatichai Faksri. 2020. “Whole-Genome Sequencing Analysis of Multidrug-Resistant Mycobacterium tuberculosis from Java, Indonesia.” Journal of Medical Microbiology 69 (7): 1013–19. https://doi.org/10.1099/jmm.0.001221.

Tuntun, Maria, Siti Aminah, and Yusrizal Ch. 2022. “Distribution Pattern and Spatial Analysis of Factors for Tuberculosis (TB) Cases in Bandar Lampung City in 2022.” Bali Medical Journal 12 (1): 50–58. https://doi.org/10.15562/bmj.v12i1.3918.

Umar, Faiqah F., Dirayah R. Husain, Mochammad M. Hatta, Rosdiana R. Natzir, Rizalinda S. Sjahril, Ressy R. Dwiyanti, Ade R. Junita, and Muhammad R. Primaguna. 2020. “Molecular Characterisation of Mutations Associated with Resistance to First- and Second-Line Drugs among Indonesian Patients with Tuberculosis.” Journal of Taibah University Medical Sciences 15 (1): 54–58. https://doi.org/10.1016/j.jtumed.2019.12.003.

Widyastuti, Setyo Dwi, Riyanto Riyanto, and Muhamad Fauzi. 2018. “Gambaran Epidemiologi Penyakit Tuberkolusis Paru (TB Paru) di Kabupaten Indramayu.” Care : Jurnal Ilmiah Ilmu Kesehatan 6 (2): 102. https://doi.org/10.33366/cr.v6i2.911.

World Health Organization. 2018. Global Tuberculosis Report 2018. Geneva: World Health Organization. https://apps.who.int/iris/handle/10665/274453.

World Health Organization. 2022. “Global Tuberculosis Report 2022.” In Global Tuberculosis Report 2022. cc bY-Nc-sa 3.0 iGo. Geneva. http://apps.who.int/iris/.

Zhang, Alice Tianbu, Martin G. Montgomery, Andrew G. W. Leslie, Gregory M. Cook, and John E. Walker. 2019. “The Structure of the Catalytic Domain of the ATP Synthase from Mycobacterium smegmatis is a Target for Developing Antitubercular Drugs.” Proceedings of the National Academy of Sciences of the United States of America 116 (10): 4206–11. https://doi.org/10.1073/pnas.1817615116.

DOI: http://dx.doi.org/10.52365/jecp.v4i2.1121